{"id":"NCT03712137","sponsor":"Allergan","briefTitle":"Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition","officialTitle":"A Multicenter, Evaluator-blinded, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-12","primaryCompletion":"2020-02-04","completion":"2021-01-26","firstPosted":"2018-10-19","resultsPosted":"2023-01-04","lastUpdate":"2023-01-04"},"enrollment":206,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Jawline Definition"],"interventions":[{"type":"DEVICE","name":"VOLUX XC","otherNames":[]},{"type":"OTHER","name":"No-treatment control","otherNames":[]}],"arms":[{"label":"VOLUX XC","type":"EXPERIMENTAL"},{"label":"No-treatment control","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition","primaryOutcome":{"measure":"Percentage of Participants Who Show ≥ 1-point Jawline Improvement on Both Sides From Baseline on the Allergan Loss of Jawline Definition Scale (ALJDS)","timeFrame":"Month 6","effectByArm":[{"arm":"No-treatment Control","deltaMin":38,"sd":null},{"arm":"VOLUX XC","deltaMin":69,"sd":null}],"pValues":[{"comp":"OG001","p":"0.0001"}]},"eligibility":{"minAge":"22 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":19,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":50},"commonTop":["HEADACHE","SEASONAL ALLERGY"]}}